Molecular basis of statin-associated myopathy

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 18-28

  Vaklavas, Christos ^a   Chatzizisis, Yiannis S ^b   Ziakas, Anthony ^c   Zamboulis, Chrysanthos ^d   Giannoglou, George D ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Molecular biology; Myopathy; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CIMETIDINE; CIPROFIBRATE; COTRIMOXAZOLE; DOLICHOL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LAMIN; METRONIDAZOLE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; RAB PROTEIN; RAS PROTEIN; ROSUVASTATIN; SELENOCYSTEINE; SELENOPROTEIN; SIMVASTATIN; UBIQUINONE; WARFARIN;

ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; MITOCHONDRIAL MYOPATHY; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN PRENYLATION; PROTEIN SYNTHESIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ATHEROSCLEROSIS; CHOLESTEROL; FEMALE; GLYCOSYLATION; GTP PHOSPHOHYDROLASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MEMBRANE PROTEINS; MUSCULAR DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UBIQUINONE;

EID: 57649158467     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.021     Document Type: Review

References (53)

1. Istvan E.S., and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 5519 (2001) 1160-1164
2. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 6257 (1990) 425-430
3. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
4. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 13 (2003) 1681-1690
5. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33 9 (2002) 2337-2341
6. Giannoglou G.D., Chatzizisis Y.S., and Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Int Med 18 2 (2007) 90-100
7. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 8A (2006) 52C-60C
8. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 6 (2004) 408-416
9. Amarenco P., Bogousslavsky J., Callahan III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 6 (2006) 549-559
10. Mukhtar R.Y., and Reckless J.P. Statin-induced myositis: a commonly encountered or rare side effect?. Curr Opin Lipidol 16 6 (2005) 640-647
11. Arora R., Liebo M., and Maldonado F. Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 11 2 (2006) 105-112
12. Antons K.A., Williams C.D., Baker S.K., and Phillips P.S. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119 5 (2006) 400-409
13. Hamelin B.A., and Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19 1 (1998) 26-37
14. Nakahara K., Kuriyama M., Sonoda Y., et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152 1 (1998) 99-106
15. Reijneveld J.C., Koot R.W., Bredman J.J., Joles J.A., and Bar P.R. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 39 6 (1996) 1028-1035
16. Masters B.A., Palmoski M.J., Flint O.P., Gregg R.E., Wang-Iverson D., and Durham S.K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131 1 (1995) 163-174
17. Gadbut A.P., Caruso A.P., and Galper J.B. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 27 10 (1995) 2397-2402
18. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19 1 (2005) 117-125
19. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 11 (2002) 1280-1287
20. Prueksaritanont T., Subramanian R., Fang X., et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30 5 (2002) 505-512
21. Owczarek J., Jasinska M., and Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57 1 (2005) 23-34
22. McTaggart S.J. Isoprenylated proteins. Cell Mol Life Sci 63 3 (2006) 255-267
23. Greenwood J., Steinman L., and Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6 5 (2006) 358-370
24. Grosshans B.L., Ortiz D., and Novick P. Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 103 32 (2006) 11821-11827
25. Calero M., Chen C.Z., Zhu W., et al. Dual prenylation is required for Rab protein localization and function. Mol Biol Cell 14 5 (2003) 1852-1867
26. Gomes A.Q., Ali B.R., Ramalho J.S., et al. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell 14 5 (2003) 1882-1899
27. Ostlund C., and Worman H.J. Nuclear envelope proteins and neuromuscular diseases. Muscle Nerve 27 4 (2003) 393-406
28. Moustafa M.E., Carlson B.A., El-Saadani M.A., et al. Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA. Mol Cell Biol 21 11 (2001) 3840-3852
29. Warner G.J., Berry M.J., Moustafa M.E., Carlson B.A., Hatfield D.L., and Faust J.R. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem 275 36 (2000) 28110-28119
30. Moghadasian M.H. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 65 13 (1999) 1329-1337
31. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145 1 (1997) 91-98
32. Nishimoto T., Tozawa R., Amano Y., Wada T., Imura Y., and Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 66 11 (2003) 2133-2139
33. Matzno S., Yamauchi T., Gohda M., et al. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res 38 8 (1997) 1639-1648
34. Morikawa S., Murakami T., Yamazaki H., et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 12 3 (2005) 121-131
35. Matzno S., Yasuda S., Juman S., et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 57 11 (2005) 1475-1484
36. Sakamoto K., Honda T., Yokoya S., Waguri S., and Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J 21 14 (2007) 4087-4094
37. Beck L.A., Hosick T.J., and Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 110 5 (1990) 1489-1499
38. Lutz R.J., Trujillo M.A., Denham K.S., Wenger L., and Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci USA 89 7 (1992) 3000-3004
39. Sinensky M., Beck L.A., Leonard S., and Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265 32 (1990) 19937-19941
40. Lammerding J., Schulze P.C., Takahashi T., et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 113 3 (2004) 370-378
41. Nikolova V., Leimena C., McMahon A.C., et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 113 3 (2004) 357-369
42. Siddals K.W., Marshman E., Westwood M., and Gibson J.M. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 279 37 (2004) 38353-38359
43. Baker S.K. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31 5 (2005) 572-580
44. Martin-Rendon E., and Blake D.J. Protein glycosylation in disease: new insights into the congenital muscular dystrophies. Trends Pharmacol Sci 24 4 (2003) 178-183
45. Marcoff L., and Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 49 23 (2007) 2231-2237
46. Chatzizisis Y.S., Vaklavas C., and Giannoglou G.D. Coenzyme q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?. Am J Cardiol 101 7 (2008) 1071
47. Caso G., Kelly P., McNurlan M.A., and Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99 10 (2007) 1409-1412
48. Young J.M., Florkowski C.M., Molyneux S.L., et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 100 9 (2007) 1400-1403
49. Paiva H., Thelen K.M., Van Coster R., et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78 1 (2005) 60-68
50. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 8A (2006) 89C-94C
51. Armitage J. The safety of statins in clinical practice. Lancet 370 9601 (2007) 1781-1790
52. Charlton-Menys V., and Durrington P.N. Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 67 1 (2007) 11-16
53. Mukhtar R.Y., Reid J., and Reckless J.P. Pitavastatin. Int J Clin Pract 59 2 (2005) 239-252